{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:18:20Z","timestamp":1792786700748,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"ational Medical Research Council","award":["NMRC\/CG\/C005\/2017,"],"award-info":[{"award-number":["NMRC\/CG\/C005\/2017,"]}],"id":[{"id":"https:\/\/ror.org\/04x3cxs03","id-type":"ROR","asserted-by":"crossref"}]},{"name":"ational Medical Research Council","award":["NMRC\/CG\/M011\/2017]."],"award-info":[{"award-number":["NMRC\/CG\/M011\/2017]."]}],"id":[{"id":"https:\/\/ror.org\/04x3cxs03","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jgar.2019.12.004","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T21:10:25Z","timestamp":1576357825000},"page":"427-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia"],"prefix":"10.1016","volume":"21","author":[{"given":"Peijun Yvonne","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze Peng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Lin Sarah","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2416-300X","authenticated-orcid":false,"given":"Sy Grace Nathalie","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Ling Cheryl","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Ling Winnie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Xuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oi Fah","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuan Tong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee Chuan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lay Hoon Andrea","family":"Kwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2019.12.004_bib0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.12.004_bib0010","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Voriconazole pharmacokinetics and therapeutic drug monitoring: a multi-center study","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.12.004_bib0015","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12185-009-0296-3","article-title":"Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders","volume":"89","author":"Ueda","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jgar.2019.12.004_bib0020","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.12.004_bib0025","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1469-0691.2009.02990.x","article-title":"Voriconazole concentrations and outcome of invasive fungal infections","volume":"16","author":"Miyakis","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2019.12.004_bib0030","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bcpt.12530","article-title":"Variability of voriconazole trough levels in haematological patients: influence of comedications with cytochrome P450 (CYP) inhibitors and\/or with CYP inhibitors plus CYP inducers","volume":"118","author":"Cojutti","year":"2016","journal-title":"Basic Clin Pharamcol Toxicol"},{"issue":"Suppl_1","key":"10.1016\/j.jgar.2019.12.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.12.004_bib0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: a prospective study","volume":"72","author":"Veringa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.12.004_bib0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijantimicag.2015.12.003","article-title":"Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections","volume":"47","author":"Lamoureux","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.12.004_bib0050","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?","volume":"34","author":"Obeng","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.jgar.2019.12.004_bib0055","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.12.004_bib0060","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jgar.2019.12.004_bib0065","first-page":"508","article-title":"CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: a systematic review","volume":"44","author":"Dorji","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jgar.2019.12.004_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169233","article-title":"Analysis of genetic variation in CYP450 genes for clinical implementation","volume":"12","author":"Goh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2019.12.004_bib0075","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/AAC.00768-12","article-title":"A simple high-performance liquid chromatography method for simultaneous determination of three triazole antifungals in human plasma","volume":"57","author":"Zhang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.12.004_bib0080","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.12.004_bib0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2019.12.004_bib0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jgar.2019.12.004_bib0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/1120009X.2018.1524085","article-title":"An observational study of the efficacy and safety of voriconazole in a real-life clinical setting","volume":"31","author":"Blanco-Dorado","year":"2019","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2019.12.004_bib0100","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/cid\/cix443","article-title":"Substantial impairment of voriconazole clearance by high-dose meropenem in a patient with renal failure","volume":"65","author":"Mahmoudi","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.12.004_bib0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12941-017-0235-8","article-title":"Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study","volume":"16","author":"Yi","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"4","key":"10.1016\/j.jgar.2019.12.004_bib0110","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/jcpt.12817","article-title":"Impact of voriconazole plasma concentrations on treatment response in critically ill patients","volume":"44","author":"Ruiz","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jgar.2019.12.004_bib0115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.jgar.2019.12.004_bib0120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijantimicag.2016.10.010","article-title":"Bioavailability of voriconazole in hospitalised patients","volume":"49","author":"Veringa","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.12.004_bib0125","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519303182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519303182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:55:57Z","timestamp":1761990957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716519303182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":25,"alternative-id":["S2213716519303182"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.12.004","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}